SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2471336543> ?p ?o ?g. }

Showing items 1 to 74 of 74 with 100 items per page.

W2471336543 abstract " ENGLISH SUMMARYPaulsen T. Recurrence of ovarian cancer and borderline ovarian tumours in Norway.Nor J Epidemiol Background: Introduction: Aim: Controversies: Material and method: Scientific significance: Plan of progress: The project is estimated to take three years. The new form in the pilot-project will be inuse from the middle of October 2001. The new form will be evaluated in January 2002. A new permanentform will then be worked out according to the experience from the pilot-form. After the end of the project inthree years, we will further analyse the 5-year relative survival.The aim of the project is to improve the quality of the data and give better knowledgeabout course and treatment of women with recurrence of ovarian cancer and BOT in Norway.All women with diagnosed ovarian/tube/perinoneal cancer and BOT as primarydisease or recurrence in Norway will be included in this study. About 500 women are diagnosed withovarian cancer annually and 330 women with recurrence. The number of BOT is approximately 130 peryear. A new registration form will be sent to all hospitals in Norway with gynaecological departments. Theform consists of clinical and pathological data. In addition we will select paraffin-embedded microscopeslides of BOT in the histological archive of the Norwegian Radium hospital; one group with primary diseaseand one group with recurrence. We will compare immunohistological characteristics of these two groups.Only a few prospective protocols have been planned or carried out internationally that wererandomised for different treatments of recurrent ovarian cancer. The studies that have been carried out haveincluded only a few patients. In our project we will collect clinical information from the whole population ofwomen with ovarian cancer and BOT in Norway. Surgery of women with recurrence of ovarian cancer inorder to achieve tumour reduction is still controversial. Some authors claim that tumour reduction surgeryimproves the survival of these patients, but this is not proven. Some authors indicate that elderly patientsmay receive less surgical and chemotherapeutic treatment without obvious clinical rationale. Today we donot know which treatment of recurrence of ovarian cancer gives the longest survival and best quality of life.The incorporation of paclitaxel into first-line therapy improves the duration of progression-free survival andoverall survival in women with incompletely-resected stage III and stage IV ovarian cancer. However we donot know which treatment gives the best overall survival in the case of recurrence. BOT are different fromthe invasive tumours of the ovary, with longer relative 5-year survival. BOT stage I has relative 5-yearsurvival of 99% and for the advanced stages 92%. Probably BOT develop through accumulation of differentgenetic mutations than invasive epithelial ovarian tumours.The main aim of this extended registration of ovarian cancer and BOT in Norway is to better documentdiagnostic procedures and treatment. We will emphasise the recurrence of ovarian cancer and BOT.The age-standardised incidence rate for ovarian cancer has increased from 11.9 per 100 000person-years in 1957 to 13.3 per 100 000 in 1997. The incidences in the Nordic countries, with the exceptionof Finland, are among the highest in the world. The borderline ovarian tumours (BOT) had an incidence rateof 4.8 per 100 000 in the period 1970 to 1993.The 5-year relative survival for patients with ovarian cancer in Norway has improved overtime, but is still less than 40%. Early diagnosis and optimal therapy can hopefully better the prognosis. Inorder to improve the techniques of examination, treatment and follow-up of these patients, the establishmentof a system for quality insurance of clinical data for cancer in Norway (NOU 20, 1997) has been suggested.According to the answers of a questionnaire that was sent to the gynaecological departments in Norway inthe spring of 2000, there were differences in how hospitals handle ovarian cancer patients.2001; 11 (2): 143-146." @default.
W2471336543 created "2016-07-22" @default.
W2471336543 creator A5001736921 @default.
W2471336543 date "2009-11-07" @default.
W2471336543 modified "2023-09-30" @default.
W2471336543 title "Tilbakefall av eggstokkreft og borderline tumorer i eggstokkene i Norge" @default.
W2471336543 cites W1710229711 @default.
W2471336543 cites W1925884553 @default.
W2471336543 cites W1968649582 @default.
W2471336543 cites W1975884493 @default.
W2471336543 cites W1978283952 @default.
W2471336543 cites W1980071452 @default.
W2471336543 cites W1985750428 @default.
W2471336543 cites W1986575178 @default.
W2471336543 cites W1989628488 @default.
W2471336543 cites W2002512099 @default.
W2471336543 cites W2005687080 @default.
W2471336543 cites W2016179096 @default.
W2471336543 cites W2030499882 @default.
W2471336543 cites W2049692414 @default.
W2471336543 cites W2053974737 @default.
W2471336543 cites W2054406953 @default.
W2471336543 cites W2057150131 @default.
W2471336543 cites W2073262519 @default.
W2471336543 cites W2077306345 @default.
W2471336543 cites W2123700442 @default.
W2471336543 cites W2133894270 @default.
W2471336543 cites W2141494978 @default.
W2471336543 cites W2145704374 @default.
W2471336543 cites W2150035097 @default.
W2471336543 cites W2263190356 @default.
W2471336543 cites W2328421677 @default.
W2471336543 cites W2419289816 @default.
W2471336543 cites W55933262 @default.
W2471336543 cites W2067383190 @default.
W2471336543 doi "https://doi.org/10.5324/nje.v11i2.548" @default.
W2471336543 hasPublicationYear "2009" @default.
W2471336543 type Work @default.
W2471336543 sameAs 2471336543 @default.
W2471336543 citedByCount "0" @default.
W2471336543 crossrefType "journal-article" @default.
W2471336543 hasAuthorship W2471336543A5001736921 @default.
W2471336543 hasBestOaLocation W24713365431 @default.
W2471336543 hasConcept C127413603 @default.
W2471336543 hasConcept C142362112 @default.
W2471336543 hasConcept C147176958 @default.
W2471336543 hasConcept C153349607 @default.
W2471336543 hasConcept C2777737414 @default.
W2471336543 hasConcept C2778753569 @default.
W2471336543 hasConceptScore W2471336543C127413603 @default.
W2471336543 hasConceptScore W2471336543C142362112 @default.
W2471336543 hasConceptScore W2471336543C147176958 @default.
W2471336543 hasConceptScore W2471336543C153349607 @default.
W2471336543 hasConceptScore W2471336543C2777737414 @default.
W2471336543 hasConceptScore W2471336543C2778753569 @default.
W2471336543 hasIssue "2" @default.
W2471336543 hasLocation W24713365431 @default.
W2471336543 hasOpenAccess W2471336543 @default.
W2471336543 hasPrimaryLocation W24713365431 @default.
W2471336543 hasRelatedWork W1542957076 @default.
W2471336543 hasRelatedWork W2086070290 @default.
W2471336543 hasRelatedWork W2255978964 @default.
W2471336543 hasRelatedWork W2296662337 @default.
W2471336543 hasRelatedWork W2468090344 @default.
W2471336543 hasRelatedWork W3106186963 @default.
W2471336543 hasRelatedWork W3125655394 @default.
W2471336543 hasRelatedWork W4206478661 @default.
W2471336543 hasRelatedWork W4236449947 @default.
W2471336543 hasRelatedWork W4245563310 @default.
W2471336543 hasVolume "11" @default.
W2471336543 isParatext "false" @default.
W2471336543 isRetracted "false" @default.
W2471336543 magId "2471336543" @default.
W2471336543 workType "article" @default.